middle.news
Racura Oncology Unveils Mechanism Behind MYC Gene Silencing by (E,E)-bisantrene at AACR 2026
11:42am on Wednesday 22nd of April, 2026 AEST
•
Healthcare
Read Story
Racura Oncology Unveils Mechanism Behind MYC Gene Silencing by (E,E)-bisantrene at AACR 2026
11:42am on Wednesday 22nd of April, 2026 AEST
Key Points
(E,E)-bisantrene stabilises G-quadruplex structures in c-MYC promoter
Strong binding affinity and gene expression suppression demonstrated
Transcriptomic effects align with other G4-binding anticancer agents
Data supports ongoing Phase 1 and Phase 3 clinical trials
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Racura Oncology (ASX:RAC)
OPEN ARTICLE